TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10765098
Drug: 3-4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 cycles of primary chemotherapy (arm B)
Study: 8653870
Drug: Age, hypertension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, hypertension, number of antianginal drugs, and ECG changes at rest
Study: 23916017
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) session
Study: 23916017
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) session
Study: 22613054
Drug: Buspirone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (60 mg/day)
Study: 17870203
Drug: Rhubarb extract
Normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb extract (20 mg kg(‐1) once a day) for 6 weeks
Study: 14666763
Drug: Qi-supplementing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-supplementing and blood-activating (QSBA) therapy
Study: 14666763
Drug: Neurotrophic agents
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotrophic agents
Study: 10953421
Drug: Thyroxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxin treatment for six months
Study: 22997787
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application combined with routine treatment of western medicine
Study: 22997787
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of western medicine
Study: 11097143
Drug: Gastro-resistant tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant tablets (500 mg)
Study: 11097143
Drug: Prolonged-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tablets (1000 mg single dose)
Study: 11097143
Drug: Oral administrations
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administrations of mesalazine
Study: 11097143
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of mesalazine suppository
Study: 11097143
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of mesalazine
Study: 9506005
Drug: Cefodizime (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (2-g intravenous dose)
Study: 9506005
Drug: Cefpirome (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (2-g intravenous dose)
Study: 8478756
Drug: Aggressive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive physical therapy for 8 weeks
Study: 25143491
Drug: e-beam sterilization
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-beam sterilization (high dose 17.1 to 21.0 kGy)
Study: 25143491
Drug: e-beam sterilization
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-beam sterilization (low dose 9.2 to 12.2 kGy)
Study: 18761816
Drug: Atomization inhalation
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomization inhalation of budesonide and terbutaline
Study: 15908196
Drug: docetaxel 85
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 85 mg/m2 i.v. on day 1 and cisplatin 40 mg/m2 i.v. on days 1 and 2 (arm A)
Study: 15908196
Drug: cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 100 mg/m2 i.v. on day 1 followed by 5‐fluorouracil 1000 mg/m2 in 24 h continuous infusion for 5 d (arm B)
Study: 1859044
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral prednisone 13, 7, and 1 hour before and 50 mg intramuscular diphenhydramine 1 hour before procedures (group I)
Study: 1859044
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral cimetidine one hour before procedure in addition to the other regimen (group II)
Study: 1859044
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral prednisone, 300 mg oral cimetidine, and 25 mg oral ephedrine one hour before procedures (group III)
Study: 1859044
Drug: Provocative dosing
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provocative dosing regimen in a separate group of ten patients whose previous reactions to RCM were life threatening (shock)
Study: 21332635
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (1- or 2-mg Prostin E2 vaginal gel)
Study: 21332635
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 tablets (3-mg Prostin E2 vaginal tablets)
Study: 15921508
Drug: Antipsychotic polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polypharmacy
Study: 10416052
Drug: Ubiquinone (Q10)
Normalized name: Ubiquinone
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubiquinone (Q10) 90 mg/day
Study: 10416052
Drug: Ubiquinone (Q10)
Normalized name: Ubiquinone
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubiquinone (Q10) 180 mg/day
Study: 7589772
Drug: SCMC‐Lys 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCMC‐Lys 900 mg three times a day (adults) or SCMC‐Lys 270 mg three times a day (children)
Study: 7589772
Drug: ABX 33
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ABX 33 mg three times a day (adults) or ABX 10 mg four times a day (children)
Study: 1693042
Drug: Tyrosine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (0.3 g/kg) and Tryptophan (0.1 g/kg) for 2 to 17 weeks
Study: 28091362
Drug: Viaskin Peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin Peanut 100 μg (VP100)
Study: 28091362
Drug: Viaskin Peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin Peanut 250 μg (VP250)
Study: 26054865
Drug: Spacer injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spacer injection (SpaceOAR system)
Study: 20979541
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Study: 20979541
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Study: 11586009
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole 1% vanishing cream
Study: 2908235
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg D-fenfluramine
Study: 3322837
Drug: Madopar HBS
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar HBS (200 mg levodopa plus 50 mg benserazide)
Study: 3322837
Drug: Madopar HBS
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar HBS (3 capsules of 125 mg)
Study: 3322837
Drug: Standard Madopar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Madopar (2 capsules of 125 mg)
Study: 31944252
Drug: Talus mobilization
Normalized name: Malus domestica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talus mobilization intervention (6 sessions of manual therapy)
Study: 18491179
Drug: Topical BoNTA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical BoNTA (CosmeTox) cream (2 U/ml)
Study: 18491179
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (without BoNTA)
Study: 10744129
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg alpha-tocopherol per day
Study: 10744129
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg alpha-tocopherol per day
Study: 10744129
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg alpha-tocopherol per day
Study: 7730690
Drug: Dronabinol 2.5
Normalized name: dronabinol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 2.5 mg twice daily
Study: 7308334
Drug: OD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD treatment group (advice and medication for OD)
Study: 7308334
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, advised to recheck OD in 2 months)
Study: 26912555
Drug: Sirolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (3 mg/d; serum target levels of 5‐10 ng/ml) added on to conventional therapy
Study: 23489975
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (PO) 182 mg
Study: 16188178
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg daily from 4 weeks before until 48 weeks after hair transplant
Study: 22719060
Drug: Riociguat 0.5
Normalized name: riociguat 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily (titrated for 8 weeks, followed by 8 weeks at stable dose)
Study: 20150526
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily + Diltiazem 60 mg 3 times daily
Study: 18689558
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg lycopene/day (placebo)
Study: 18689558
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg lycopene/day
Study: 18689558
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lycopene/day
Study: 18689558
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lycopene/day
Study: 10867376
Drug: Allergen specific
Normalized name: Allergen specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen specific immunotherapy with birch and/or timothy pollen allergen extract
Study: 10584290
Drug: Optimal pharmacotherapy
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacotherapy (Control)
Study: 8803358
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sexual communication and self-management skills
Study: 1794369
Drug: Single-dose ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ornidazole
Study: 25270214
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC), 3 tablets each time, tid, n=70
Study: 25270214
Drug: Salicylazosulfapyridine (SASP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylazosulfapyridine (SASP), 4 pills each time, bid, n=70
Study: 20518806
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg QD for 12 weeks
Study: 20518806
Drug: Dapagliflozin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 20 mg QD for 12 weeks
Study: 9432341
Drug: RBC400 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC400 + CLAR (Ranitidine bismuth citrate 400 mg bid with clarithromycin 250 mg qid for 14 days)
Study: 9432341
Drug: RBC800 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC800 + CLAR (Ranitidine bismuth citrate 800 mg bid with clarithromycin 250 mg qid for 14 days)
Study: 9432341
Drug: RBC400 (Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC400 (Ranitidine bismuth citrate 400 mg bid alone for 4 weeks)
Study: 7523450
Drug: 0.30 mg
Normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg DEP nasal challenge
Study: 30830474
Drug: UDCA 400
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 400 mg daily for 2 weeks
Study: 30830474
Drug: UDCA 800
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 800 mg daily for 2 weeks
Study: 30830474
Drug: UDCA 1200
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 1200 mg daily for 2 weeks
Study: 26749073
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (EPA + DHA; 8-10 g over 2-5 days preoperatively, then 2 g/day postoperatively)
Study: 17392540
Drug: Metformin (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500-1000 mg twice daily)
Study: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I/IGFBP‐3 (0.1 mg/kg.d)
Study: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I/IGFBP‐3 (0.4 mg/kg.d)
Study: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I/IGFBP‐3 (0.8 mg/kg.d)
Study: 11591843
Drug: Pulsed IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed IV methylprednisolone (IVMP) - 1 g/day for 5 days every 4 months for 3 years, then every 6 months for 2 years
Study: 8059023
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEpo) treatment
Study: 8059023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hemodialysis and rHuEpo
Study: 28780563
Drug: Multi-modal support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal support service programme including mail-delivered cognitive behavioural therapy, telephone-delivered group counselling, and education on community services/resources.
Study: 26505201
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (60-minute session twice a week for 8 weeks)
Study: 24565712
Drug: FENO-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO-guided treatment
Study: 18463442
Drug: Pentagastrin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentagastrin (6 microg/kg) during placebo treatment
Study: 18463442
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg bid) treatment
Study: 15345738
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg/day) combined with testosterone injections (100 mg/week)
Study: 15345738
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg/day) combined with placebo injections
Study: 15345738
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg/day) combined with resistance training
Study: 15345738
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg/day) combined with resistance training and testosterone
Study: 8803642
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo injections)
Study: 9071805
Drug: Experimental stimuli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental stimuli (combinations of corn syrup and water with viscosities ranging from 2 to 2,240 cP)
Study: 2429334
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tiropramide per day
Study: 2429334
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg imecromone per day
Study: 31340206
Drug: Neo-adjuvant Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant Chemoradiation Therapy (NACRT)
Study: 31340206
Drug: Neo-adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant Chemotherapy (NAC)
Study: 27678438
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (3 g/day) with a low-calorie diet
Study: 27678438
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/day) with a low-calorie diet
Study: 20235203
Drug: Varicella vaccine
Normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicella vaccine (VV)
Study: 18514633
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (AAs) supplementation, 70.6 kcal/day (8 g of AA snacks) given at 10.00 am and 5.00 pm
Study: 15885167
Drug: Rhubarb administration
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb administration before operation and at 1 day and 2 days after operation
Study: 15885167
Drug: Rhubarb administration
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb administration
Study: 15885167
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rhubarb administration)
Study: 11952024
Drug: Emedastine difumarate
Normalized name: Emedastine Difumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine difumarate 0.05% ophthalmic solution
Study: 2277475
Drug: Streptokinase (1,000,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1,000,000 units intravenously) followed by intravenous heparin for 5-7 days
Study: 7157926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no streptokinase treatment)
Study: 30777957
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of intravenous cefazolin 1 g at surgery (Group A)
Study: 30777957
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin 500 mg postoperatively twice a day for 5 days (Group B)
Study: 21372561
Drug: Gentamicin/heparin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin/heparin (group A)
Study: 21372561
Drug: Heparin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (group C)
Study: 17264338
Drug: Oral uracil/ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uracil/ftorafur (UFT) plus leucovorin (LV)
Study: 9233710
Drug: pp65 antigenemia-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pp65 antigenemia-guided early ganciclovir treatment
Study: 8013155
Drug: Neoadjuvant combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant combination therapy with flutamide and Lupron for 3 months
Study: 3626867
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms Cr + 100 mg nicotinic acid
Study: 3626867
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nicotinic acid
Study: 21546629
Drug: CEM‐102 loading‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEM‐102 loading‐dose regimen (1500 mg twice per day on day 1 followed by 600 mg twice per day)
Study: 21546629
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg twice per day)
Study: 9029449
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) + 2.5 mg chlorhexidine (CHX)
Study: 3552680
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg tds
Study: 3552680
Drug: Verapamil 40
Normalized name: verapamil 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 40 mg tds
Study: 3552680
Drug: Verapamil (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (higher doses)
Study: 21353251
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume index ≥40 mL/m²
Study: 21353251
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume index <40 mL/m²
Study: 19039965
Drug: Propofol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target controlled infusion; 2-3 mcg x ml(‐1))
Study: 12689610
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 50 nmol of Neuropeptide Y (NPY)
Study: 10513708
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg daily on 2 consecutive days
Study: 10513708
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution given in the same manner as IVIG)
Study: 27578972
Drug: Home-based spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Study: 27578972
Drug: In-clinic spirometry
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Study: 19320650
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium tolerance test (OCTT) with a 10-mmol calcium dose